EFFICACY AND SAFETY IN HIGH‐RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB. (12th June 2019) - Dreyling, M.